Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altace Revascularization Benefit Is Clear But Inappropriate For Label - Cmte.

Executive Summary

King Pharmaceuticals' ACE inhibitor Altace is clearly beneficial in reducing the need for revascularization, but inclusion of the claim in labeling may inappropriately influence clinical practice, members of FDA's Cardio-Renal Drugs Advisory Committee said.

You may also be interested in...



King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients

Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.

King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients

Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.

Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal

Wyeth-Ayerst is allocating approximately 1,000 sales reps to promote King's Altace in the U.S. and Puerto Rico, under a copromotion agreement announced June 23.

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel